N/A
Completed N=22
Testing of a New Therapeutic Vibration Device to Reduce Neuromuscular Weakness in Hospitalized Patients
Critically Ill · Post Intensive Care Syndrome
Source: ClinicalTrials.gov NCT03479008 ↗
Enrolled (actual)
22
Serious AEs
0.0%
Results posted
May 2024
Primary outcomePrimary: Change in Regional Hemoglobin Oxygen Saturation — 75.65; 77.01; 73.83; 77.09 percent of oxygenation — p=<0.0001
Summary
Objective: Test the ability of vibration to produce physiologic, biochemical, and anatomic changes consistent with exercise that would help prevent the development of muscle weakness that occurs when patients are immobile for long periods of time.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Regional Hemoglobin Oxygen Saturation |
75.65; 77.01; 73.83; 77.09; 72.23; 74.15 | <0.0001 sig |
| PRIMARY VO2 and VCO2 |
3.19; 3.84; 2.54; 3.07 | <0.0001 sig |
| PRIMARY Energy Expenditure |
1.12; 1.35 | <0.0001 sig |
| PRIMARY Minute Variation |
7.09; 8.50 | <0.0001 sig |
| PRIMARY Tidal Volume |
0.55; 0.68 | 0.094 |
| PRIMARY EMG |
13.10; 62.67; 5.15; 11.59; 3.17; 7.14 | 0.011 sig |
Eligibility Criteria
Exclusion Criteria
- Known pregnancy
- Prisoner
Data sourced from ClinicalTrials.gov (NCT03479008). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.